<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73953</article-id><article-id pub-id-type="doi">10.7554/eLife.73953</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Arbidol inhibits human esophageal squamous cell carcinoma growth <italic>in vitro</italic> and <italic> in vivo</italic> through suppressing ataxia telangiectasia and Rad3-related protein kinase</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-261965"><name><surname>Yang</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262856"><name><surname>Lu</surname><given-names>Xuebo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217541"><name><surname>Jiang</surname><given-names>Yanan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262857"><name><surname>Zhao</surname><given-names>Lili</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262858"><name><surname>Wang</surname><given-names>Donghao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262859"><name><surname>Wei</surname><given-names>Yaxing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262860"><name><surname>Yu</surname><given-names>Yin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262866"><name><surname>Kim</surname><given-names>Myoung Ok</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262862"><name><surname>Laster</surname><given-names>Kyle Vaughn</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262863"><name><surname>Li</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262864"><name><surname>Yuan</surname><given-names>Baoyin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-195780"><name><surname>Dong</surname><given-names>Zigang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-195779"><name><surname>Liu</surname><given-names>Kangdong</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4425-5625</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pathophysiology</institution>, <institution>Zhengzhou University</institution>, <addr-line><named-content content-type="city">Zhengzhou</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">Department of Animal Science and Biotechnology</institution>, <institution>Kyungpook National University</institution>, <addr-line><named-content content-type="city">Sangju</named-content></addr-line>, <country>Republic of Korea</country></aff><aff id="aff3"><institution>China-US  Hormel Cancer Institute</institution>, <addr-line><named-content content-type="city">Zhengzhou</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-238838"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Reviewing editor</role><aff><institution>Brown University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>dongzg@zzu.edu.cn</email> (ZD);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>kdliu@zzu.edu.cn</email> (KL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>09</day><month>09</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e73953</elocation-id><history><date date-type="received"><day>16</day><month>09</month><year>2021</year></date><date date-type="accepted"><day>08</day><month>09</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Yang et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Yang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73953-v1.pdf"/><abstract><p>Human esophageal cancer has a global impact on human health due to its high incidence and mortality. Therefore, there is an urgent need to develop new drugs to treat or prevent the prominent pathological subtype of esophageal cancer, esophageal squamous cell carcinoma. Based upon a screening of drugs approved by the Food and Drug Administration, we discovered that Arbidol could effectively inhibit the proliferation of human esophageal squamous cell carcinoma <italic>in vitro</italic>. Next, we conducted a series of cell-based assays and found that Arbidol treatment inhibited the proliferation and colony formation ability of ESCC cells and promoted G1 phase cell cycle arrest. Phospho-proteomics experiments, <italic>in vitro</italic> kinase assays and pull-down assays were subsequently performed in order to identify the underlying growth inhibitory mechanism. We verified Arbidol is a potential ATR inhibitor via binding to ATR kinase to reduce the phosphorylation and activation of MCM2 at Ser108. Finally, we demonstrated Arbidol had the inhibitory effect of ESCC <italic>in vivo</italic> by a PDX model. All together, Arbidol inhibits the proliferation of ESCC <italic>in vitro</italic> and <italic>in vivo</italic> through the DNA replication pathway and is associated with the cell cycle.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81872335</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Kangdong</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>National Natural Science Youth Foundatio of China</institution></institution-wrap></funding-source><award-id>81902486</award-id><principal-award-recipient><name><surname>Jiang</surname><given-names>Yanan</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Natural Science Foundation of Henan</institution></institution-wrap></funding-source><award-id>161100510300</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Kangdong</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>The Central Plains Science and Technology Innovation Leading Talents</institution></institution-wrap></funding-source><award-id>224200510015</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Kangdong</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Compliance with Ethics RequirementsIn this study, we established  an ESCC PDX model. In this model,  the tumor sample  from an ESCC patient was EG20 (ESCC, male, T2N0M0II, moderately differentiated, obtained from Linzhou Cancer Hospital, Henan Province, China). The patient was fully informed of the study and provided consent. This study was approved by the Ethics Committee of Zhengzhou University (ZZUHCI-2019012).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the iProX partner repository with the dataset identifier PXD034944.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Jiang Y</collab><collab>Liu K</collab></person-group><year iso-8601-date="2022">2022</year><source>Proteomics analysis report of  esophageal squamous cell carcinoma treated by Arbidol</source><ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD034944">http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD034944</ext-link><comment>ProteomeXchange Consortium, PXD034944</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-73953-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>